# reload+after+2024-01-23 17:45:10.838681
address1§Cheung Kong Center
address2§48th Floor 2 Queen's Road
city§Central
country§Hong Kong
phone§852 2121 8200
fax§852 2128 1778
website§https://www.hutch-med.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
fullTimeEmployees§1990
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Chi Keung  To ACGI, B.Sc., M.B.A.', 'age': 71, 'title': 'Executive Chairman', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 85000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Wei-Guo  Su B.Sc., Ph.D.', 'age': 65, 'title': 'CEO, Chief Scientific Officer & Executive Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 1972000, 'exercisedValue': 0, 'unexercisedValue': 2421833}, {'maxAge': 1, 'name': 'Mr. Chig Fung  Cheng BEc, CA', 'age': 56, 'title': 'CFO & Executive Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 886000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Edith  Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E', 'age': 71, 'title': 'Company Secretary & Non-Executive Director', 'yearBorn': 1952, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Karen Jane  Atkin', 'age': 57, 'title': 'Executive VP & COO', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'David  Ng', 'title': 'Head of Investor Relations & Capital Strategies', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Charles George Rupert  Nixon', 'age': 53, 'title': 'Group General Counsel', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kin Hung  Lee M.B.A.', 'age': 46, 'title': 'Senior Vice President of Corporate Management & Communications', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Selina  Zhang', 'title': 'Senior Vice President of Global Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Qingmei  Wang Ph.D.', 'age': 60, 'title': 'Senior Vice President of Business Development & Strategic Alliances', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§4
compensationRisk§8
shareHolderRightsRisk§5
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.625
priceToSalesTrailing12Months§3.9438648
currency§USD
dateShortInterest§1702598400
forwardEps§-1.04
exchange§NMS
quoteType§EQUITY
shortName§HUTCHMED (China) Limited
longName§HUTCHMED (China) Limited
firstTradeDateEpochUtc§1458135000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§449b4879-f77b-3306-a602-ec54c57e4c31
gmtOffSetMilliseconds§-18000000
targetHighPrice§50.0
targetLowPrice§14.6
targetMeanPrice§30.95
targetMedianPrice§29.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§3.006
grossMargins§0.033469997
ebitdaMargins§-0.12042
trailingPegRatio§None
